T2	control 72 90	Chemotherapy Alone
T3	condition 367 389	skeletal complications
T4	ethinicity 693 698	Asian
T5	eligibility 699 749	patients with HER2-negative invasive breast cancer
T6	No-of-participants 813 841	One hundred and eighty-eight
T7	control-participants 895 897	95
T8	intervention-participants 921 923	93
T9	duration 925 954	from March 2010 to April 2012
T10	No-of-participants 960 963	180
T11	outcome-Measure 1298 1339	pathological complete response (pCR) rate
T12	outcome 1550 1562	rates of pCR
T13	intervention-value 1577 1582	14.8%
T14	control-value 1609 1613	7.7%
T15	outcome 1759 1767	pCR rate
T16	intervention-value 1799 1804	18.4%
T17	control-value 1809 1813	5.1%
T18	outcome 1768 1794	in postmenopausal patients
T19	outcome 1909 1952	patients with triple-negative breast cancer
T20	intervention-value 1957 1962	35.3%
T21	control-value 1967 1972	11.8%
T1	intervention 31 46	Zoledronic Acid
T22	intervention 52 64	Chemotherapy
